TScan Therapeutics (TCRX) Operating Expenses (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Operating Expenses data on file, last reported at $30.1 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 21.6% year-over-year to $30.1 million in Q1 2026; TTM through Mar 2026 was $137.8 million, a 4.36% decrease from a year earlier, with the FY2025 full-year figure at $146.1 million, up 6.18% from the prior year.
• Operating Expenses for Q1 2026 stood at $30.1 million, up from $26.4 million in the prior quarter.
• Over the last five years, Operating Expenses for TCRX reached as high as $41.7 million in Q2 2025 and fell as low as $19.2 million in Q1 2022.
• Historically, Operating Expenses has averaged $29.9 million across 5 years, with a median of $29.5 million in 2023.
• Across the five-year window, Operating Expenses soared 92.9% in 2022 and fell 29.3% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $21.7 million in 2022, then surged by 31.38% to $28.6 million in 2023, then surged by 30.84% to $37.4 million in 2024, then decreased by 29.3% to $26.4 million in 2025, then climbed by 13.99% to $30.1 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $30.1 million in Q1 2026, $26.4 million in Q4 2025, and $39.6 million in Q3 2025.